Ablation beats drug therapy for women and men with A-fib

(HealthDay)—For patients with atrial fibrillation (AF), those undergoing ablation have a significantly reduced risk for recurrent AF compared with those receiving drug therapy, regardless of sex, according to a study published in the Feb. 16 issue of Circulation.

Andrea M. Russo, M.D., from Cooper Medical School of Rowan University in Camden, New Jersey, and colleagues examined outcomes for 819 women and 1,385 men with AF ages 65 years and older or aged younger than 65 years with at least one risk factor for stroke. Participants were randomly assigned to either with pulmonary vein isolation or drug therapy with rate/rhythm control agents.

The researchers found that during the index procedure, women were less likely than men to have ancillary ablation procedures performed (55.7 versus 62.2 percent); in both sexes, complications from treatment occurred infrequently. For the primary outcome of death, disabling stroke, serious bleeding, or , the hazard ratio was 1.01 (95 percent confidence interval, 0.62 to 1.65) for women and 0.73 (95 percent confidence interval, 0.51 to 1.05) for men for ablation versus drug therapy. Compared with those receiving drug therapy, patients undergoing ablation had a significantly reduced risk for recurrent AF, but the effect was greater for men (hazard ratio, 0.48; 95 percent confidence interval, 0.40 to 0.58) than women (hazard ratio, 0.64; 95 percent confidence interval, 0.51 to 0.82).

“When compared with , ablation offers comparable benefits for women and men,” the authors write. “Consequently, sex should not be used as a basis for selecting a management strategy for the treatment of AF.”

Several authors disclosed financial ties to pharmaceutical and medical device companies, some of which funded the study.


Ablation cuts risk of recurrent stroke in patients with A-fib


More information:
Abstract/Full Text (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved.

Citation:
Ablation beats drug therapy for women and men with A-fib (2021, February 16)
retrieved 16 February 2021
from https://medicalxpress.com/news/2021-02-ablation-drug-therapy-women-men.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Health News

Study finds cancer immunotherapy treatment can reverse HIV latency

Credit: Pixabay/CC0 Public Domain An international research collaboration has found the cancer immunotherapy treatment, pembrolizumab, can reverse HIV latency, the ability for the virus to ‘hide’ inside cells of people living with HIV on antiretroviral therapy, the major barrier to a cure for HIV. Pembrolizumab is a monoclonal antibody that reverses the ‘exhaustion’ of the […]

Read More
Health News

Gene therapy for the treatment of Huntington’s disease

Credit: Pixabay/CC0 Public Domain Gene therapy targeting the messenger RNA (mRNA) of the mutated huntingtin gene (HTT) can provide long-lasting therapeutic benefit in Huntington’s disease after a single administration. An adeno-associated virus (AAV) gene therapy containing a primary artificial microRNA (pri-amiRNA) targeting HTT mRNA is described in the peer-reviewed journal Human Gene Therapy. “The challenge […]

Read More
Health News

MRI of hand, foot may predict rheumatoid arthritis in undifferentiated arthritis

(HealthDay)—Magnetic resonance imaging (MRI) of the hand and foot may predict rheumatoid arthritis (RA) in patients presenting with undifferentiated arthritis (UA), according to a study published online Jan. 12 in Rheumatology. Nikolet K. den Hollander, M.D., Ph.D., from the Leiden University Medical Center in the Netherlands, and colleagues studied the predictive value of MRI for […]

Read More